

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**

**Proposed Single Technology Appraisal (STA)**

**Vernakalant for the treatment of recent onset atrial fibrillation**

**Provisional matrix of consultees and commentators**

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Merck Sharp &amp; Dohme (vernakalant)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action Heart</li> <li>• Afiya Trust</li> <li>• AntiCoagulation Europe (ACE)</li> <li>• Arrhythmia Alliance (AFA Affiliated)</li> <li>• Atrial Fibrillation Association (AFA)</li> <li>• Black Health Agency</li> <li>• British Cardiac Patients Association</li> <li>• Chinese National Healthy Living Centre</li> <li>• Counsel and Care</li> <li>• Different Strokes</li> <li>• Equalities National Council</li> <li>• Heart Care Partnership (UK)</li> <li>• HEART UK</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Stroke Association</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Anticoagulation Specialist Association (ASA)</li> <li>• British Association for Nursing in Cardiac Care</li> <li>• British Association for Service to the Elderly</li> <li>• British Association of Stroke Physicians</li> <li>• British Cardiovascular Intervention Society (BCIS)</li> <li>• British Cardiovascular Society</li> <li>• British Geriatrics Society</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Board of Community Health Councils in Wales</li> <li>• British Cardiovascular Industry Association</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• NHS Quality Improvement Scotland</li> <li>• Public Health Wales NHS Trust</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Possible comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• Abbott Laboratories (propafenone)</li> <li>• International Medication Systems (amiodarone)</li> <li>• Meda Pharmaceuticals (flecainide)</li> <li>• Sanofi-aventis (amiodarone)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• British Society for Cardiovascular Research [BCS affiliated]</li> <li>• Cardiovascular Diseases Specialist Library (CVDSL)</li> <li>• Central Cardiac Audit Database</li> <li>• Cochrane Heart Group</li> <li>• Cochrane Stroke Group</li> <li>• CORDA</li> </ul>

## Appendix C

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• British Heart Foundation</li> <li>• British Society for Haematology</li> <li>• British Society for Haemostasis and Thrombosis (BSHT)</li> <li>• British Society for Heart Failure</li> <li>• Clinical Leaders of Thrombosis (CLOT)</li> <li>• Heart Rhythm UK</li> <li>• National Heart Forum (UK)</li> <li>• National Pharmacy Association</li> <li>• Primary Care Cardiovascular Society</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society for Cardiological Science &amp; Technology</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• Vascular Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS Bromley</li> <li>• Sunderland NHS Teaching PCT</li> <li>• Welsh Assembly Government</li> </ul>	<ul style="list-style-type: none"> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• Policy Research Institute on Ageing and Ethnicity</li> <li>• Research Institute for the Care of Older People</li> <li>• Wellcome Trust - Cardiovascular Research Initiative</li> </ul> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• Evidence Review Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Clinical Guidelines Centre</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• tbc</li> </ul>

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

### ***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

#### **Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit and the *British National Formulary*).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.